Skip to main content
Premium Trial:

Request an Annual Quote

ScienceWerke, SciGene, KFB, Genomatix, Beckman Coulter

Premium

ScienceWerke Will Distribute SciGene Products in Singapore, Malaysia

SciGene said this week that it has signed a distribution agreement with ScienceWerke, and that ScienceWerke now has exclusive rights to market and support products manufactured by SciGene in Singapore and Malaysia.

According to SciGene, ScienceWerke's SciGene portfolio will include its Hybex Microarray Incubation System and its Little Dipper Microarray Processor, as well as its BriteSpot Microarray Workstation.

Financial details were not discussed.


KFB adds Genomatix Chip Analysis Pipeline to Service

The Center of Excellence for Fluorescent Bioanalysis, or KFB, an authorized Affymetrix service provider, has signed an agreement with Genomatix Software that will enable KFB to offer Genomatix's GeneChip Analysis-Pipeline to KFB's industrial and academic customers, Genomatix said last week.

KFB customers will now receive results for their microarray experiments based on both KFB's and Genomatix's technology. In addition, they will have temporary access to Genomatix's BiblioSphere PathwayEdition, a database and analysis system, as well as data processed with Genomatix's ChipInspector data analysis tool.

Financial details were not discussed.


Beckman Coulter's Q4 Revenues Fall 5.4 Percent

Beckman Coulter reported last week that its fourth-quarter sales fell by 5.4 percent to $655.5 million from $693 million during the year-ago period. Fourth-quarter consumable sales were up 12 percent, with acquisitions contributing to 3.9 percent of that growth.

Net income for the period decreased 70 percent to $17.8 million from $59.8 million during the fourth quarter of 2004.

Beckman reaffirmed its outlook for 2006 that was stated on Nov. 2, 2005, when the company released its third-quarter earnings report. Assuming stable currency, sales should be in the range of $2.53 billion to $2.60 billion, the company said.

For the first quarter of the year, sales should be $555 million to $575 million, Beckman said.

Beckman did not break out its R&D spending for the fourth quarter or for the 2005 year.

As of Dec. 31, 2005, Beckman had $57.6 million in cash and cash equivalents.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.